Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 10,492 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 3 Interventional

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

NCT01893307
View directory record Official record
Conditions
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

NCT05731271
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
Interventions
TST003
Drug
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Portland, Oregon • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 2 Interventional Results available

PhII ICb With/Without Erbitux in MBC Pts

NCT00248287
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

Mobility Training Using Exoskeletons for Functional Recovery After Stroke

NCT02128152
View directory record Official record
Conditions
Severe Stroke or Similar Neurological Muscle Weakness
Interventions
Ekso exoskeleton
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

Weight, Energy, Lipids, and the Liver (WELL) Study

NCT05199948
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
Soybean Oil Foods, Palm Oil Foods
Other
Lead sponsor
Ohio State University
Other
Eligibility
22 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients

NCT05226078
View directory record Official record
Conditions
Chronic Insomnia, Cancer-related Problem/Condition, Cancer-Related Syndrome
Interventions
Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

RELAX: Reducing Length of Antibiotics for Children With Ear Infections

NCT05608993
View directory record Official record
Conditions
Acute Otitis Media, Pediatric Infectious Disease, Ear Infection
Interventions
High Intensity Intervention, Low Intensity Intervention
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
2 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 2 Interventional Results available

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

NCT00999804
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib, Letrozole, Trastuzumab
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting No phase listed Observational

Impella Supported OPCABG

NCT04339452
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Impella 5.5 with SmartAssist Supported OPCABG
Device
Lead sponsor
Lucian Archambault Durham III
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 3 Interventional

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT06596252
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

The Group Risk Reduction Intervention Therapy (GRRIT) Project

NCT05401838
View directory record Official record
Conditions
Suicidal Ideation, Suicide, Attempted, Coping Skills, Depression, Anxiety, PTSD
Interventions
Group Brief Cognitive-Behavioral Therapy (G-BCBT), Dialectical Behavior Therapy (DBT) Skills Group
Behavioral
Lead sponsor
University of North Carolina, Charlotte
Other
Eligibility
18 Years to 99 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

Peer Coaching Intervention in Young Adults With Congenital Heart Disease

NCT04271358
View directory record Official record
Conditions
Congenital Heart Disease, Congenital Heart Defect
Interventions
Peer Health Coaching
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 26 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

NCT02081326
View directory record Official record
Conditions
Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes, Covid19
Interventions
Bacillus Calmette-Guérin, Saline injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 2 Interventional

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

NCT03333616
View directory record Official record
Conditions
Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Non-adenocarcinoma Prostate Cancer, Refractory Germ-cell, High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

NCT02420847
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
Interventions
Doxorubicin Hydrochloride, Gemcitabine Hydrochloride, Ixazomib Citrate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

Nutritional Intervention for Endometriosis

NCT05175248
View directory record Official record
Conditions
Endometriosis
Interventions
Plant-based Intervention Group
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions
Durvalumab, External Beam Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting No phase listed Observational

Delirium in Children Undergoing Stem Cell Transplantation

NCT04937400
View directory record Official record
Conditions
Stem Cell Transplant Complications, Delirium
Interventions
Daily screening for delirium
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Up to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 2 Interventional

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107
View directory record Official record
Conditions
Breast Carcinoma, Breast Lump, Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Peau d'Orange, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Panitumumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 3 Interventional

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411
View directory record Official record
Conditions
Vitiligo
Interventions
Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 1 Interventional

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

NCT04428671
View directory record Official record
Conditions
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions
Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Radiation · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Phase 3 Interventional

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 5, 2026, 6:24 AM EST
Active, not recruiting Not applicable Interventional

Walking Rehabilitation After Spinal Cord Injury: Locomotor Training Using Adaptive Robotics

NCT03504826
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Hybrid Assistive Limb (HAL)
Device
Lead sponsor
Brooks Rehabilitation
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 6:24 AM EST